GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection. GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Etanercept | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Etanercept. |
| Peginterferon alfa-2a | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Peginterferon alfa-2a. |
| Interferon alfa-n1 | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-n1. |
| Interferon alfa-n3 | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-n3. |
| Peginterferon alfa-2b | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Peginterferon alfa-2b. |
| Anakinra | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Anakinra. |
| Interferon gamma-1b | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon gamma-1b. |
| Interferon alfa-2a | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2a. |
| Aldesleukin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldesleukin. |
| Adalimumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Adalimumab. |
| Gemtuzumab ozogamicin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Pegaspargase | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pegaspargase. |
| Infliximab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab. |
| Interferon beta-1b | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon beta-1b. |
| Interferon alfacon-1 | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfacon-1. |
| Trastuzumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trastuzumab. |
| Rituximab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Rituximab. |
| Basiliximab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Basiliximab. |
| Muromonab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Muromonab. |
| Ibritumomab tiuxetan | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan. |
| Tositumomab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tositumomab. |
| Alemtuzumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab. |
| Cyclosporine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine. |
| Alefacept | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept. |
| Efalizumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2b. |
| Natalizumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Natalizumab. |
| Daclizumab | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daclizumab. |
| Phenylalanine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Phenylalanine. |
| Bortezomib | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bortezomib. |
| Cladribine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cladribine. |
| Carmustine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Carmustine. |
| Amsacrine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Amsacrine. |
| Bleomycin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bleomycin. |
| Chlorambucil | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Chlorambucil. |
| Raltitrexed | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Raltitrexed. |
| Mitomycin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mitomycin. |
| Bexarotene | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bexarotene. |
| Vindesine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vindesine. |
| Floxuridine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Floxuridine. |
| Indomethacin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Indomethacin. |
| Tioguanine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tioguanine. |
| Vinorelbine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vinorelbine. |
| Dexrazoxane | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dexrazoxane. |
| Sorafenib | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Sorafenib. |
| Streptozocin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Streptozocin. |
| Trifluridine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trifluridine. |
| Gemcitabine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemcitabine. |
| Teniposide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Teniposide. |
| Epirubicin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Epirubicin. |
| Chloramphenicol | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Chloramphenicol. |
| Lenalidomide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Lenalidomide. |
| Altretamine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Altretamine. |
| Zidovudine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Zidovudine. |
| Cisplatin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cisplatin. |
| Oxaliplatin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Oxaliplatin. |
| Cyclophosphamide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclophosphamide. |
| Vincristine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vincristine. |
| Fluorouracil | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Fluorouracil. |
| Propylthiouracil | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Propylthiouracil. |
| Pentostatin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pentostatin. |
| Methotrexate | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Methotrexate. |
| Carbamazepine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Carbamazepine. |
| Vinblastine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Vinblastine. |
| Linezolid | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Linezolid. |
| Imatinib | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Imatinib. |
| Clofarabine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Clofarabine. |
| Pemetrexed | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pemetrexed. |
| Mycophenolate mofetil | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mycophenolate mofetil. |
| Daunorubicin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daunorubicin. |
| Irinotecan | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Irinotecan. |
| Methimazole | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Methimazole. |
| Etoposide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Etoposide. |
| Sulfasalazine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Sulfasalazine. |
| Dacarbazine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dacarbazine. |
| Temozolomide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Temozolomide. |
| Penicillamine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Penicillamine. |
| Tacrolimus | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tacrolimus. |
| Sirolimus | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Sirolimus. |
| Mechlorethamine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mechlorethamine. |
| Azacitidine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Azacitidine. |
| Carboplatin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Carboplatin. |
| Dactinomycin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Dactinomycin. |
| Azathioprine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Azathioprine. |
| Doxorubicin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Doxorubicin. |
| Hydroxyurea | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Hydroxyurea. |
| Busulfan | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Busulfan. |
| Mycophenolic acid | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mycophenolic acid. |
| Topotecan | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Topotecan. |
| Mercaptopurine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mercaptopurine. |
| Thalidomide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Thalidomide. |
| Melphalan | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Melphalan. |
| Fludarabine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Fludarabine. |
| Leflunomide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Leflunomide. |
| Flucytosine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Flucytosine. |
| Capecitabine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Capecitabine. |
| Procarbazine | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Procarbazine. |
| Arsenic trioxide | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Arsenic trioxide. |
| Idarubicin | The therapeutic efficacy of GI-5005 can be decreased when used in combination with Idarubicin. |